Management of hypertension: summary of NICE guidance
====================================================


In a rapid response to this Practice article by Taryn Krause and colleagues (*BMJ* 2010;343:d4891 doi:[10.1136/bmj.d4891](https://www.bmj.com/lookup/doi/10.1136/bmj.d4891)), Kate Harding and colleagues write that it “does not mention that women of child bearing potential should not be treated with either ACE inhibitors or ARBs without a detailed discussion of the teratogenic potential of these drugs, and advice to discontinue them preferably prior to conception” ([www.bmj.com/content/343/bmj.d4891.extract/reply#bmj\_el\_269620](http://www.bmj.com/content/343/bmj.d4891.extract/reply#bmj\_el\_269620)). In reply, the authors acknowledge the omission from this summary document but point out that the full NICE guidance does contain specific recommendations on the subject ([www.bmj.com/content/343/bmj.d4891.extract/reply#bmj\_el_270204](http://www.bmj.com/content/343/bmj.d4891.extract/reply#bmj_el_270204)).

## Notes

**Cite this as:** *BMJ* 2011;343:d6255